EVOLUTION OF COVX-BODIES

Peptides and monoclonal antibodies have emerged as important therapeutics, but each still have many limitations. Peptides are highly potent, but frequently are poor therapeutics due to rapid degradation in the body and frequency of administration. Traditional monoclonal antibodies have more favorable pharmacokinetics, but are often constrained by a challenging and lengthy development process.

The CovX technology is based on a novel approach that addresses these limitations by combining the strengths of peptides and antibodies into a new molecule. This molecule, called a CovX-Body, has both the pharmacologic properties of the peptide and the pharmacokinetic properties of monoclonal antibodies.